Johnson & Johnson (NYSE: JNJ) has a price-to-earnings ratio of 28.36x that is above its average ratio. Additionally, the 36-month beta value for JNJ is 0.53. There are mixed opinions on the stock, with 7 analysts rating it as a “buy,” 4 rating it as “overweight,” 12 rating it as “hold,” and 0 rating it as “sell.”
The public float for JNJ is 2.40B and currently, short sellers hold a 0.66% ratio of that float. The average trading volume of JNJ on April 01, 2024 was 7.09M shares.
JNJ) stock’s latest price update
Johnson & Johnson (NYSE: JNJ) has seen a rise in its stock price by 0.15 in relation to its previous close of 157.96. However, the company has experienced a 1.57% gain in its stock price over the last five trading sessions. The Motley Fool reported 2024-03-30 that Now that it’s focused on just medical technology and pharmaceuticals, Johnson & Johnson’s pace of annual dividend raises could accelerate. Medtronic is the largest publicly traded medical device manufacturer, and it offers a 3.3% yield at recent prices.
JNJ’s Market Performance
Johnson & Johnson (JNJ) has experienced a 1.57% rise in stock performance for the past week, with a -2.08% drop in the past month, and a 1.18% rise in the past quarter. The volatility ratio for the week is 0.98%, and the volatility levels for the past 30 days are at 1.21% for JNJ. The simple moving average for the last 20 days is -0.26% for JNJ stock, with a simple moving average of -0.81% for the last 200 days.
Analysts’ Opinion of JNJ
Many brokerage firms have already submitted their reports for JNJ stocks, with Wells Fargo repeating the rating for JNJ by listing it as a “Equal Weight.” The predicted price for JNJ in the upcoming period, according to Wells Fargo is $163 based on the research report published on December 13, 2023 of the previous year 2023.
UBS, on the other hand, stated in their research note that they expect to see JNJ reach a price target of $180, previously predicting the price at $167. The rating they have provided for JNJ stocks is “Buy” according to the report published on December 01st, 2023.
RBC Capital Mkts gave a rating of “Outperform” to JNJ, setting the target price at $178 in the report published on October 05th of the previous year.
JNJ Trading at -0.38% from the 50-Day Moving Average
After a stumble in the market that brought JNJ to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -10.10% of loss for the given period.
Volatility was left at 1.21%, however, over the last 30 days, the volatility rate increased by 0.98%, as shares sank -1.98% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -1.40% lower at present.
During the last 5 trading sessions, JNJ rose by +1.57%, which changed the moving average for the period of 200-days by -1.07% in comparison to the 20-day moving average, which settled at $158.45. In addition, Johnson & Johnson saw 0.93% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at JNJ starting from Broadhurst Vanessa, who sale 8,891 shares at the price of $162.16 back on Mar 13 ’24. After this action, Broadhurst Vanessa now owns 15,043 shares of Johnson & Johnson, valued at $1,441,765 using the latest closing price.
JOHNSON & JOHNSON, the 10% Owner of Johnson & Johnson, sale 3,725 shares at $25.81 during a trade that took place back on Feb 16 ’24, which means that JOHNSON & JOHNSON is holding 4,099,575 shares at $96,142 based on the most recent closing price.
Stock Fundamentals for JNJ
Current profitability levels for the company are sitting at:
- 0.26 for the present operating margin
- 0.68 for the gross margin
The net margin for Johnson & Johnson stands at 0.15. The total capital return value is set at 0.2. Equity return is now at value 18.57, with 7.62 for asset returns.
Based on Johnson & Johnson (JNJ), the company’s capital structure generated 0.3 points at debt to capital in total, while cash flow to debt ratio is standing at 0.78. The debt to equity ratio resting at 0.43. The interest coverage ratio of the stock is 18.17.
Currently, EBITDA for the company is 29.34 billion with net debt to EBITDA at 0.27. When we switch over and look at the enterprise to sales, we see a ratio of 4.19. The receivables turnover for the company is 6.25for trailing twelve months and the total asset turnover is 0.56. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.16.
Conclusion
In conclusion, Johnson & Johnson (JNJ) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
